The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Bradycardia
Publications
ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report.
Medicine 2019 Mar;98;e14826 — 2019 Mar — e14826
Severe bradycardia associated with crizotinib.
Postgraduate medical journal 2017 12;93;774-775 — 2017 12 — 774-775
Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Lung cancer (Amsterdam, Netherlands) 2015 Feb;87;89-95 — 2015 Feb — 89-95
Girard N, Audigier-Valette C, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlési F
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
Expert review of anticancer therapy 2015 Feb;15;225-33 — 2015 Feb — 225-33
Asymptomatic profound sinus bradycardia (heart rate ?45) in non-small cell lung cancer patients treated with crizotinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011 Dec;6;2135-7 — 2011 Dec — 2135-7